Stockscreener 앱 받기
7.48
1.43%
0.13
전일 마감가:
$7.35
열려 있는:
$7.34
하루 거래량:
108.58K
Relative Volume:
0.25
시가총액:
$212.32M
수익:
$67.22M
순이익/손실:
$-65.78M
주가수익비율:
-3.134
EPS:
-2.3867
순현금흐름:
$-79.02M
1주 성능:
+10.94%
1개월 성능:
+2.12%
6개월 성능:
+8.99%
1년 성능:
-44.20%
1일 변동 폭
$7.30
$7.54
1주일 범위
$6.74
$8.28
52주 변동 폭
$5.85
$24.17
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
명칭
Arcturus Therapeutics Holdings Inc
전화
(858) 900-2660
주소
10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
7.47 | 206.92M | 67.22M | -65.78M | -79.02M | -2.3867 |
VRTX
Vertex Pharmaceuticals Inc
|
520.41 | 134.02B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
670.00 | 68.59B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
925.27 | 58.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.90 | 41.76B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
189.76 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-18 | 개시 | B. Riley Securities | Buy |
| 2026-01-23 | 개시 | Roth Capital | Buy |
| 2025-10-24 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-10-23 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-10-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2025-09-04 | 재개 | H.C. Wainwright | Buy |
| 2025-05-28 | 개시 | Scotiabank | Sector Outperform |
| 2025-01-28 | 개시 | BTIG Research | Buy |
| 2024-08-12 | 개시 | Leerink Partners | Outperform |
| 2023-12-13 | 개시 | Canaccord Genuity | Buy |
| 2023-07-24 | 개시 | William Blair | Outperform |
| 2023-05-11 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-11-14 | 재개 | Wells Fargo | Overweight |
| 2022-11-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2022-11-03 | 업그레이드 | Citigroup | Neutral → Buy |
| 2022-11-02 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2022-08-10 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2022-07-19 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-05-11 | 업그레이드 | Robert W. Baird | Underperform → Neutral |
| 2022-04-21 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2022-01-31 | 업그레이드 | Raymond James | Underperform → Mkt Perform |
| 2021-08-12 | 다운그레이드 | Raymond James | Mkt Perform → Underperform |
| 2021-08-11 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-08-10 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2021-07-02 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-06-25 | 재개 | Goldman | Neutral |
| 2021-06-21 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2021-06-04 | 재개 | Robert W. Baird | Neutral |
| 2021-02-17 | 다운그레이드 | B. Riley Securities | Neutral → Sell |
| 2021-01-19 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-15 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-01-07 | 개시 | Wells Fargo | Overweight |
| 2020-12-29 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2020-12-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-29 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-12-29 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-12-23 | 다운그레이드 | ROTH Capital | Buy → Sell |
| 2020-12-08 | 재확인 | B. Riley Securities | Buy |
| 2020-12-07 | 재확인 | B. Riley Securities | Buy |
| 2020-10-26 | 개시 | Barclays | Overweight |
| 2020-10-06 | 개시 | Citigroup | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-30 | 재개 | ROTH Capital | Buy |
| 2020-07-16 | 개시 | Raymond James | Outperform |
| 2020-07-13 | 개시 | B. Riley FBR | Buy |
| 2020-06-09 | 다운그레이드 | WBB Securities | Buy → Hold |
| 2020-02-11 | 개시 | Robert W. Baird | Outperform |
| 2020-02-07 | 개시 | Guggenheim | Buy |
| 2020-02-06 | 개시 | Guggenheim | Buy |
| 2019-04-05 | 개시 | H.C. Wainwright | Buy |
| 2018-09-20 | 업그레이드 | WBB Securities | Buy → Strong Buy |
| 2018-01-22 | 개시 | Chardan Capital Markets | Buy |
모두보기
Arcturus Therapeutics Holdings Inc 주식(ARCT)의 최신 뉴스
Arcturus partners with Thermo Fisher for cystic fibrosis drug - Investing.com
Arcturus Therapeutics Announces Strategic Collaboration with Thermo Fisher Scientific to Advance ARCT-032 for Cystic Fibrosis - Business Wire
Price to earnings forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell Small Cap Comp Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2500 Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 2000 Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Arcturus Therapeutics Holdings Inc.(NasdaqGM:ARCT) dropped from Russell 3000 Growth Benchmark - marketscreener.com
Enterprise value to EBITDA forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
Enterprise value to EBIT forward of Arcturus Therapeutics Holdings Inc. – NASDAQ:ARCT - TradingView
Arcturus Therapeutics Holdings, Inc. Actuals & Estimates (NASDAQ:ARCT) - TradingView
ARCT Forecast — Price Target — Prediction for 2027 - TradingView
Arcturus Therapeutics Holdings Inc (ARCT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Discipline and Rules-Based Execution in ARCT Response - Stock Traders Daily
ARCT SEC FilingsArcturus Therape 10-K, 10-Q, 8-K Forms - Stock Titan
Arcturus Therapeutics Holdings Inc (ARCT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
ARCT Q1 2026 Earnings: Narrower-than-expected loss highlights clinical momentumMid-Term Outlook - newsline.com
Arcturus Therapeutics Holdings Inc (ARCT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Arcturus Therapeutics Holdings Inc - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Institutional Confidence - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Arcturus Therapeutics Holdings Inc (ARCT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Arcturus Therapeutics | 4: Statement of changes in beneficial ownership of securities-Director HOLMES EDWARD W - Moomoo
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 grant - Stock Titan
Director Peter Farrell receives 15,000 Arcturus (NASDAQ: ARCT) stock options - Stock Titan
Director at Arcturus (NASDAQ: ARCT) receives 15,000 stock options grant - Stock Titan
Arcturus Therapeutics (ARCT) director awarded 15,000 stock options at $7.30 - Stock Titan
Arcturus (NASDAQ: ARCT) director receives 15,000 stock options as 2026 board grant - Stock Titan
Board member at Arcturus (NASDAQ: ARCT) receives 15,000 stock options - Stock Titan
Arcturus (ARCT) director Jing L. Marantz granted 15,000 stock options - Stock Titan
Arcturus Therapeutics highlights mRNA pipeline, CF data and vaccine expansion at Jefferies - MSN
ARCT Q1 2026 Earnings: Narrower-than-Expected Loss Despite No RevenueProfit Margin Analysis - Město Břeclav
Behavioral Patterns of ARCT and Institutional Flows - Stock Traders Daily
mRNA Vaccines and Therapeutics Market Size, Share, Growth, 2034 - Straits Research
Arcturus Therapeutics Holdings Inc. 2026 Annual Shareholder Meeting Results and Election of Directors - Minichart
Arcturus Shareholders Back Board, Pay, and Auditor - TipRanks
Arcturus Therapeutics (ARCT) holders elect board, approve pay and auditor - Stock Titan
Arcturus Therapeutics Highlights mRNA Pipeline, CF Data and Vaccine Expansion at Jefferies - inkl
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
Arcturus Stock Faces a Big 72 Hours: What Could Move ARCT Next - Bez Kabli
Arcturus Therapeutics Holds Steady at $7.92 as Market Awaits CatalystsMomentum ETF - newsline.com
(ARCT) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Is Arcturus Therapeutics Poised for a Massive Upside in 2026 - Kavout
Arcturus Therapeutics (ARCT) Holds Steady at $7.92 – Waiting for a CatalystTriple EMA - newsline.com
Arcturus Therapeutics presents research on mRNA therapy for inherited metabolic disorders at SIMD 2026 - Traders Union
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Arcturus Therapeutics (ARCT) Surges 6.2% as Buyers Defend Key SupportFibonacci Extension - thelegaladvocate.com
Arcturus Therapeutics urges new solutions as 10 percent of cystic fibrosis patients still lack effective treatment - Traders Union
Arcturus Therapeutics to Present at 2026 Jefferies Global Healthcare Conference - BioSpace
Arcturus Therapeutics Holdings Inc (ARCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.82%
0.85%
자본화:
|
볼륨(24시간):